Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
1820603-32-4 | Methyl 5-BOC-6-methyl-4-oxo-6H,7H-pyrazolo[1,5-a]pyrazine-2-carboxylate | AA00I0CR | MFCD28166389
1820641-61-9 | 1,3-Dimethyl 2-(5-methyl-3-nitropyridin-2-yl)propanedioate | AA00I0JY | MFCD28096661
1820686-50-7 | 3-Bromo-5-nitro-4-(propylamino)benzonitrile | AA00I0SA | MFCD26383429
1820734-39-1 | 4-(2-Methylpropyl)morpholine-2-carboxamide | AA00I0ZU | MFCD26523319
1823856-54-7 | 5-tert-Butyl 7-ethyl 6,7-dihydropyrazolo[1,5-a]pyrazine-5,7(4h)-dicarboxylate | AA00I17X | MFCD28119022
1845713-77-0 | tert-butyl N-(5-bromo-6-chloropyridin-2-yl)carbamate | AA00I1FD | MFCD28515410
18655-47-5 | Triformylmethane | AA00I1QZ | MFCD08752565
1887240-36-9 | 2,6-Dichloro-4-(trifluoromethyl)phenylboronic acid | AA00I2OJ | MFCD27935761
1936-15-8 | Orange G | AA00I2WW | MFCD00012457
1951444-50-0 | 1-(4-Nitrophenyl)-2-oxopyridine-3-carboxylic acid | AA00I38X | MFCD29764424